NCT07229586 2025-12-19
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT03834948 2023-08-22
AO-176 in Multiple Solid Tumor Malignancies
Arch Oncology
Phase 1/2 Completed
NCT03588039 2023-05-19
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Athenex, Inc.
Phase 1 Terminated
NCT03894540 2022-09-13
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
Phase 1 Terminated
NCT04035473 2022-04-13
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Athenex, Inc.
Phase 1 Completed
NCT02730481 2021-09-13
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Athenex, Inc.
Phase 1 Completed
NCT04180384 2021-07-29
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Athenex, Inc.
Phase 2 Completed
NCT04802980 2021-07-28
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Huabo Biopharm Co., Ltd.
Phase 1 Unknown
NCT04046016 2019-08-06
A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor
Seoul National University Hospital
Phase EARLY_PHASE1 Completed
NCT02593708 2017-11-17
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
University of California, San Francisco
Phase 1 Terminated